Table 6.

Characteristics of patients diagnosed with lung disorders associated with bortezomib

Gender	Age (years)	Type of myeloma	M protein (g/dL)	ISS stage	KPS	Plasma cell (%)	Smoking	Past history of lung disease	KL‐6	Dose level (mg/m2)	Diagnosis of adverse events by investigators	Diagnosis of adverse events by the committee	Grade	Cycle	Study drugs	Treatment for lung injury	Outcome
Woman	70s	IgG‐λ	6.6	II	100	25.4	No	None	148	0.7	Pneumonitis suspected	ILD	1	4	Discontinued	No	Not recovered
Man	60s	IgG‐κ	2.8	III	100	54	Yes	None	180	0.7	Interstitial pneumonitis	ILD	2	3	Discontinued	No	Recovered
Woman	70s	IgG‐κ	4.4	II	90	41.8	No	None	207	1.3	SpO2 decreased	Oxygen saturation decreased	1	2	Continued	No	Recovered
Man	70s	IgG‐κ	4.1	I	80	17.5	Yes	Effort dyspnea	229	1.3	Hypoxia	ILD	1	1	Continued	No	Recovered
Man	70s	IgG‐κ	5.4	I	90	34.4	Yes	None	169	1.3	Hypoxia	Hypoxia	2	1	Discontinued	No	Recovered
Woman	70s	IgA‐κ	0.8	II	100	50a	No	None	310	1.3	Interstitial pneumonitis	ILD	1	3	Discontinued	No	Not recovered
Woman	60s	IgA‐κ	3.4	II	80	20.4	No	None	68	1.3	Pneumonitis suspected	Hypoxia	3	1	Dose reduction after transient cessation	Steroid pulse	Recovered
											Pneumonitis suspected	Hypoxia	3	2	Dose reduction after transient cessation	Steroid pulse	Recovered
											Hypoxia	Hypoxia	2	2	Continued	No	Recovered
Woman	60s	IgG‐κ	6.8	II	90	12.5	No	None	199	1.3	Hypoxia	Hypoxia	3	1	Transient cessation	Oxygen administration	Recovered
Woman	70s	BJP	6.2 g/day	III	90	30	No	None	151	1.3	Pneumonitis	ILD	1	1	Continued	No	Not recovered
Woman	80s	IgG‐λ	3.8	II	90	14.2	No	None	311	1.3	Hypoxia	ILD	1	1	Transient cessation	No	Recovered
Woman	80s	IgG‐λ/BJP	6.6	II	90	41.8	No	None	398	1.3	Pneumonitis suspected	ILD	1	2	Continued	No	Not recovered

^aIndicates data from bone marrow biopsy (other data from bone marrow aspiration). BJP, Bence Jones protein; ILD, interstitial lung disease; ISS, international staging system; KL‐6, Krebs von den Lungen‐6; KPS, Karnofsky performance status; M protein, monoclonal protein.